Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diet, Gut Microbiome, and Microbial Metabolites in Inflammatory Bowel Disease: From Functional Dysbiosis to Precision Nutrition.

International journal of molecular sciences·2026
Same author

Temporal Dynamics of Catestatin Across Gestation: Links to Metabolic and Hemodynamic Adaptation.

Life (Basel, Switzerland)·2026
Same author

Lean Mass and Musculoskeletal Preservation in GLP-1-Based Obesity Treatment: Nutrition, Exercise, Supplementation, and Monitoring Strategies.

Metabolites·2026
Same author

Molecular determinants of thromboinflammatory activation in inflammatory bowel disease.

Journal of molecular medicine (Berlin, Germany)·2026
Same author

Natural Bioactive Compounds Targeting Gut Barrier Integrity and Metabolic Endotoxemia in Cardiometabolic Disease: Mechanistic Insights and Translational Perspectives.

Molecules (Basel, Switzerland)·2026
Same author

Agreement Between Intraoperative Findings and Histopathological Diagnosis and Their Association with Postoperative Outcomes in Acute Appendicitis.

Diagnostics (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 13, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

Extra-Virgin Olive Oil Phenolics in IBD-Associated Vascular Risk.

Roko Šantić1,2, Marko Kumrić1,2, Lovre Martinović1

  • 1Department of Pathophysiology, University of Split School of Medicine, 21000 Split, Croatia.

Molecules (Basel, Switzerland)
|June 12, 2026
PubMed
Summary
This summary is machine-generated.

High-phenolic extra-virgin olive oil (EVOO) phenolics show potential for managing inflammatory bowel disease (IBD) complications. Further clinical trials are needed to confirm EVOO

Keywords:
endothelial dysfunctionextra-virgin olive oilgut–vascular axishydroxytyrosolinflammatory bowel diseaseoleaceinoleocanthalplatelet activationsecoiridoidsthromboinflammation

More Related Videos

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Related Experiment Videos

Last Updated: Jun 13, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Area of Science:

  • Nutritional Science
  • Gastroenterology
  • Cardiovascular Research

Background:

  • Inflammatory bowel disease (IBD) involves chronic intestinal inflammation, linked to endothelial injury, platelet hyperreactivity, and increased cardiovascular risk.
  • Extra-virgin olive oil (EVOO) is rich in bioactive phenolic compounds, including hydroxytyrosol, tyrosol, and secoiridoids, which possess antioxidant and anti-inflammatory properties.
  • The gut-endothelium-platelet axis is implicated in IBD-related vascular and thromboinflammatory complications.

Purpose of the Study:

  • To review the potential role of EVOO phenolics in modulating the gut-endothelium-platelet axis in the context of IBD.
  • To evaluate the evidence for EVOO phenolics impacting epithelial barrier integrity, immune signaling, antioxidant defense, and vascular/platelet pathways relevant to IBD.

Main Methods:

  • Narrative review of existing literature on EVOO phenolics, their metabolism, and biological effects.
  • Focus on specific phenolic compounds like hydroxytyrosol, tyrosol, oleuropein, ligstroside derivatives, oleocanthal, and oleacein.
  • Analysis of evidence linking EVOO phenolics to pathways involved in IBD and cardiovascular complications.

Main Results:

  • EVOO phenolics demonstrate plausible effects on epithelial barrier function, TLR4/NF-κB signaling, and Nrf2-mediated antioxidant defense.
  • Evidence suggests potential benefits in reducing oxidized LDL formation, endothelial activation, and influencing platelet-related pathways.
  • Current clinical data specifically in IBD patients is limited; most findings are derived from non-IBD studies or in vitro models.

Conclusions:

  • EVOO phenolics may offer therapeutic potential for IBD-associated vascular and thromboinflammatory issues.
  • Further research, including chemically characterized, biomarker-anchored intervention trials in IBD patients, is essential.
  • High-phenolic EVOO cannot yet be recommended as a validated strategy for cardiovascular risk modification in IBD.